In addition, during the course of HER2-positive breast cancer, a change in tumor expression of HER2 is associated with poor survival outcome and makes it difficult to select an optimal systemic therapy for either the adjuvant or recurrent metastatic setting (17–21). Here, ERBB2 is linked to breast cancer.